These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33820922)

  • 1. Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases.
    Lauko A; Thapa B; Sharma M; Muhsen B; Barnett A; Rauf Y; Borghei-Razavi H; Tatineni V; Patil P; Mohammadi A; Chao S; Murphy ES; Angelov L; Suh J; Barnett GH; Nowacki AS; Pennell N; Ahluwalia MS
    Sci Rep; 2021 Apr; 11(1):7490. PubMed ID: 33820922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases.
    Lauko A; Kotecha R; Barnett A; Li H; Tatineni V; Ali A; Patil P; Mohammadi AM; Chao ST; Murphy ES; Angelov L; Suh JH; Barnett GH; Pennell NA; Ahluwalia MS
    Sci Rep; 2021 Sep; 11(1):18174. PubMed ID: 34518623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment.
    Hirasawa Y; Kubota Y; Mura E; Suzuki R; Tsurui T; Iriguchi N; Ishiguro T; Ohkuma R; Shimokawa M; Ariizumi H; Horiike A; Wada S; Ariyoshi T; Goto S; Otsuka K; Murakami M; Kiuchi Y; Yoshimura K; Hoffman RM; Tsunoda T
    Anticancer Res; 2024 Aug; 44(8):3397-3407. PubMed ID: 39060084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis.
    Jessurun CAC; Hulsbergen AFC; de Wit AE; Tewarie IA; Snijders TJ; Verhoeff JJC; Phillips JG; Reardon DA; Mekary RA; Broekman MLD
    Neuro Oncol; 2021 Aug; 23(8):1261-1272. PubMed ID: 33631792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the combination of platelet count and neutrophil-lymphocyte ratio and prognosis of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study.
    Kashimura S; Sato M; Inagaki T; Kin M; Manabe R; Kusumoto S; Horiike A; Tsunoda T; Kogo M
    Thorac Cancer; 2024 Oct; 15(28):2049-2060. PubMed ID: 39193939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
    Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U
    J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
    Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
    Front Immunol; 2021; 12():697298. PubMed ID: 34858389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis.
    Kang S; Jeong H; Park JE; Kim HS; Kim YH; Lee DH; Kim SW; Lee JC; Choi CM; Yoon S
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4523-4532. PubMed ID: 36136277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
    Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
    BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
    Front Immunol; 2021; 12():651086. PubMed ID: 34248939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
    Takamori S; Komiya T; Powell E
    Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
    Guo D; Jin F; Jing W; Li M; Chen D; Zou B; Jiang G; Fu L; Zhu H; Kong L; Wu J; Yu J; Yue J
    Clin Lung Cancer; 2019 Nov; 20(6):412-419. PubMed ID: 31300364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.